• Group sales up 26% to A$68.2m
• U.S. sales up 25.3% to A$51.7m
• NovoSorb MTX sales up 195.2% to A$6.2m

PolyNovo Limited (ASX: PNV) has reported indicative trading results for the first half of FY26, highlighting strong growth across its key markets and product portfolio. Group sales reached A$68.2 million, up 26% on the prior corresponding period (STLY: A$54.1 million), with the U.S. market delivering a 25.3% increase to A$51.7 million. The company's NovoSorb MTX product line saw exceptional growth of 195.2% to A$6.2 million, while the Rest of World segment also performed strongly, up 28.3% to A$16.5 million. BARDA revenue declined 62.5% to A$2.0 million, in line with expectations as the Pivotal Trial for full-thickness burns was completed. The company reported positive cash flow from operations of A$9.5 million, a significant turnaround from the A$12.5 million outflow in the prior corresponding period. PolyNovo's new CEO, Bruce Peatey, expressed confidence in the company's continued momentum, highlighting the strong adoption of the NovoSorb platform and the transformation in the U.S. skin substitute market. The company remains focused on supporting its customers, broadening its product and indication base, and exploring opportunities for further growth, including through CMS coverage.

PolyNovo expects to deliver continued strong growth in the second half of FY26, supported by the broader adoption of its NovoSorb platform and the transformation in the U.S. skin substitute market.

PolyNovo is focused on ongoing strong growth in the second half of FY26, ensuring it supports its customers, and broadening the product and indication base for its portfolio. The company is also examining opportunities for additional growth, including through CMS coverage.